Quarterly Update: September 2025 Highlights

As the year continues to gather pace, the past quarter has been about sharpening focus: on our science, on how we work with partners, and on where Nucleic Acid Nanorobotics can have the greatest long-term impact. From deep technical discussions on the future of molecular programming to meeting partners on the ground in the US, it’s been an energising and productive period for the team. Here’s a snapshot of what we’ve been up to.

1. Shaping the Next Decade of Molecular Programming in Seattle

Earlier this quarter, we attended Molecular Flight Plan in Seattle - a focused meeting bringing together leading experts in molecular programming, DNA nanotechnology, and related disciplines. The goal was ambitious: to help shape a shared vision for the field's direction over the next 10 years.

These discussions went well beyond near-term applications, covering foundational challenges, emerging opportunities, and the kinds of tools and infrastructure the community will need to unlock the next wave of progress. Being part of this conversation reinforces our belief that programmable nucleic acid systems will play a central role in future biomedicine, therapeutics and diagnostics, and that building robust, deployable platforms now is critical.

For our partners, this means we’re not just solving today’s problems, but actively designing technology with longevity and scalability in mind.

2. A One-Minute Introduction to Nanovery and NANs

As part of the BioTools Innovator programme, we released a short, one-minute video introducing Nanovery and our Nucleic Acid Nanorobotics platform.

In a deliberately concise format, the video captures the essence of Nanovery and NANs, and why this approach enables simpler, faster, and more adaptable bioanalysis for oligonucleotide therapeutics.

You can watch the video here:

If you’re new to Nanovery, it’s a quick way to understand what we do. If you’ve been following our journey, it reflects how far the platform has matured.

3. A Fruitful Trip to Boston: Conferences and Conversations

Boston was a major focus this quarter. Over a single trip, we attended three key conferences:

1. 4th Oligonucleotides Analytical Development & CMC Summit
2. 5th Oligonucleotides for CNS Summit
3. RNA Leaders Boston

Across these meetings, we engaged in detailed discussions around PK bioanalysis, CNS delivery challenges, assay sensitivity, and the growing complexity of oligonucleotide modalities. Just as importantly, we spent time meeting with local biotech and pharma companies across the Boston area, deepening existing relationships and starting new ones.

These conversations continue to shape how we prioritise new capabilities within the NANs platform, ensuring what we build maps directly to real-world needs in discovery and development.

4. Welcoming Estela to the Team

This quarter also marked an important internal milestone: Estela joined Nanovery to lead and strengthen our business development operations.

She’s integrated incredibly quickly and has already helped streamline how we engage with partners - from first conversations, through scoping, to project delivery. The result is a clearer, smoother, and more predictable experience for companies working with us.

As our science scales, making Nanovery easy to work with is just as important as technical performance. Estela’s arrival has allowed the wider team to focus even more sharply on what we do best: building and deploying high-quality nanorobotic assays that solve hard bioanalytical problems.

Looking Ahead

The coming months will see us continue to expand the scope of the NANs platform, progress ongoing partner projects, and share more of what we’re learning along the way. With stronger foundations - both scientifically and operationally - we’re excited about what this next phase enables.

If you’re working with ASOs, siRNA, or emerging oligonucleotide modalities and looking for simpler, more adaptable bioanalysis, we’re actively supporting partners in this space and would be happy to talk.

Thanks for following our journey, exciting times ahead!